NLRP3 inhibitor reduces inflammatory biomarkers in high-risk patients

A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high inflammatory risk, according to the results of a trial presented at the European Atherosclerosis Society Congress. The NLRP3 inhibitor, ruvonoflast (NodThera), “is designed to directly inhibit activation of the NLRP3 inflammasome in multiple clinically relevant cell

Raccontata dahealio.com